No Data
No Data
Hong Kong Stock Concept Tracking | Beijing introduces policies to support the high-quality development of innovative pharmaceuticals, institutions are optimistic about the rise of the domestic innovative drug industry chain (with concept stocks)
Various departments including the Beijing Municipal Medical Security Administration and the Beijing Drug Administration issued a number of measures to support the high-quality development of innovative medicines in Beijing
Is Akeso, Inc. (HKG:9926) Trading At A 47% Discount?
Key Insights The projected fair value for Akeso is HK$90.01 based on 2 Stage Free Cash Flow to Equity Current share price of HK$47.95 suggests Akeso is potentially 47% undervalued Analyst price t
[Broker Focus] CITIC Construction Investment maintains Kangfang Biotech's (09926) “buy” rating, indicating that the company's investment is expected to be realized at an accelerated pace in various fields
Jin Wu Financial News | According to CITIC Construction Investment Research Report, Kang Fang Biotech (09926) released first-line AK104 gastric cancer data at the AACR conference. The mid-term analysis yielded positive results: regardless of PD-L1 expression, the Cardonil combination regimen was significantly superior to chemotherapy. The company's 2024 recommendations focus on: (1) AK104 first-line cervical cancer NDA; (2) AK112 approved for marketing in China, head-to-head K drug data read, US completed enrollment, etc.; (3) PCSK9, IL12/23, etc. were approved for listing; (4) domestic NDAs and IL4R entry of the self-exempt drug IL17
Changes in Hong Kong stocks | Kangfang Biotech (09926) is now up more than 4%. Brilliant data on gastric cancer is expected to drive the evolution of gastric cancer treatment pattern
The Zhitong Finance App learned that Kang Fang Biotech (09926) is now up more than 4%. As of press release, it has risen 3.97% to HK$48.5, with a turnover of HK$125 million. According to the news, the positive analysis results of the phase III clinical study of Kangfang Biotech's core product, cardonil combined chemotherapy for first-line gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, were published in an oral report at the 2024 American Cancer Association Annual Meeting (AACR). The overall data was impressive. Guotai Junan pointed out that data shows that cardonil has the benefit advantage of the entire population and is expected to drive the evolution of gastric cancer treatment patterns. Currently on the front line of Cardonelli
Akeso to Raise Over HK$1 Billion Via Share Sale
Akeso (HKG:9926) has mandated Morgan Stanley Asia and CLSA to sell 24.8 million of its shares to no less than six placees at HK$47.65 apiece, according to a Thursday filing with the Hong Kong bourse.
[Broker Focus] Debon Securities maintains Kangfang Biotech's (09926) “buy” rating and is expected to enter a period of rapid performance growth in the next 2-3 years
Jinwu Financial News | According to Debon Securities Research, Kangfang Biotech (09926) recorded total revenue of 4,526 billion yuan in 2023, an increase of 440% over the previous year. Product sales in 2023 were $1,631 million (up 48% year over year), and the company confirmed annual technical licensing and technical cooperation revenue of about RMB 2,923 billion, mainly from the initial payment of the AK112, PD-1/VEGF (, PD-1/VEGF) license from Summit. Profit in 2023 was $1,942 million. According to the bank, the company invested a total of 1,254 billion yuan in R&D throughout the year. At the end of 2023,
No Data